Compare FirstEnergy Corp. (FE) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Heron Therapeutics Inc — how do they compare? FirstEnergy Corp. trades at $44.9 (market cap $25.80B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: FirstEnergy Corp. is far larger — about 348.5× Heron Therapeutics Inc's market cap, and FirstEnergy Corp. pays a 4.17% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and Heron Therapeutics Inc for 35 Days on average.
| FE | HRTX | |
|---|---|---|
Market Cap | $25.80B | $74.04M |
Volume | 5,328,616 | 3,668,095 |
Sector | Utilities | Health |
52-Week High | $51.91 | $1.49 |
52-Week Low | $43.04 | $0.27 |
Typical Hold Time | 71 Days | 35 Days |
Enterprise Value | $54.72B | $180.78M |
Dividend Yield | 4.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $44.85, up 1.33% with mixed technical signals showing bullish overall but bearish moving averages. The company reported Q1 2026 EPS beat but missed Q4 2025 and Q2 2026 expectations, with Q3 2026 results pending. Revenue grew to $15.09B in 2025 with stable profit margins around 6.86%. Recent developments include the $36B Energize365 investment plan and consistent dividend payments, supporting long-term growth prospects in the utility sector.
FE presents a moderate buy opportunity with analyst consensus target of $52.80 offering 17.7% upside. Strong institutional interest and dividend stability balance execution risks from heavy capital expenditures and debt levels. The stock's valuation appears reasonable with P/E of 23.84, though investors should monitor earnings consistency and regulatory developments in the electric utility space.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
